Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

Hematol Oncol. 2017 Dec;35(4):914-917. doi: 10.1002/hon.2320. Epub 2016 Jul 12.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Aged
  • Depsipeptides / administration & dosage*
  • Depsipeptides / adverse effects
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Lymphoma, T-Cell, Peripheral / mortality*
  • Male
  • Middle Aged
  • Recurrence
  • Survival Rate

Substances

  • Depsipeptides
  • romidepsin